Company: DAWN
Filing Date: 2025-01-13
Form Type: 8-K
Source: 0001193125-25-005012
Chunk: 0

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-01-13
Form: 8-K
Item: Item 2.02
Chunk 0
---
Item 2.02      Results of Operations and Financial Condition.  

On January 13, 2025, Day One Biopharmaceuticals, Inc. (the “ Company”) issued a press release announcing its preliminary unaudited OJEMDA net product revenue results for the fourth quarter and the year ended December 31, 2024 and cash, cash equivalents and short-term investments as of December 31, 2024. A copy of the Company’s press release is attached hereto as Exhibit 99.1.

The Company has not yet completed its financial close process for the year ended December 31, 2024.

The preliminary financial metrics and results included in this Current Report on Form8-Kare estimates that have not been audited and are subject to the completion of the Company’s financial closing procedures and any adjustments. The preliminary results may differ materially from the actual results that will be reflected in the Company’s financial statements when they are completed and publicly disclosed.